The estimated Net Worth of Ronald D Boyd is at least 399 千$ dollars as of 15 December 2017. Ronald Boyd owns over 25,000 units of Rockwell Medical Inc stock worth over 275,930$ and over the last 21 years Ronald sold RMTI stock worth over 123,200$.
Ronald has made over 11 trades of the Rockwell Medical Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently Ronald exercised 25,000 units of RMTI stock worth 162,500$ on 15 December 2017.
The largest trade Ronald's ever made was exercising 25,000 units of Rockwell Medical Inc stock on 15 December 2017 worth over 162,500$. On average, Ronald trades about 4,645 units every 100 days since 2003. As of 15 December 2017 Ronald still owns at least 67,300 units of Rockwell Medical Inc stock.
You can see the complete history of Ronald Boyd stock trades at the bottom of the page.
Ronald's mailing address filed with the SEC is 1912 WEST HAMPTON POINT DRIVE, , STATESBORO, GA, 30458.
Over the last 21 years, insiders at Rockwell Medical Inc have traded over 3,082,721$ worth of Rockwell Medical Inc stock and bought 689,891 units worth 3,959,861$ . The most active insiders traders include Robert L Chioini、David S.Rbi Private Investm...、Thomas E Klema. On average, Rockwell Medical Inc executives and independent directors trade stock every 45 days with the average trade being worth of 170,433$. The most recent stock trade was executed by David S.Rbi Private Investm... on 21 December 2020, trading 42,450 units of RMTI stock currently worth 43,724$.
rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www
Rockwell Medical Inc executives and other stock owners filed with the SEC include: